查詢結果分析
相關文獻
- Guillain-Barre'-like Syndrome after Nelarabine Treatment
- Guillain-Barre'症候群患者之護理
- 糖尿病周圍神經病變之研究
- Cutaneous Thermal Thresholds in Normal Subjects and Diabetic Patients Without Symptoms of Peripheral Neuropathy
- Effectiveness of Traditional Chinese Medicine for Diabetic Neuropathy--A Review
- 糖尿病的遠端對稱性神經病變
- 糖尿病周圍神經病變
- 大家要注意蛋中雞的周圍神經病變[Gall & Gimeno, 2018, Avian Pathology]
- Relationship between Peripheral Vessels and Electrophysiological Examination in Patients with Diabetic Peripheral Neuropathy
- 少腹逐瘀湯加減對疼痛性糖尿病周圍神經病變療效研究
頁籤選單縮合
題 名 | Guillain-Barre'-like Syndrome after Nelarabine Treatment=Nelarabine治療後產生多發性神經病變 |
---|---|
作 者 | 許雅婷; 陳彩雲; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 1:2 2014.09[民103.09] |
頁 次 | 頁124-127 |
分類號 | 418.31 |
關鍵詞 | 奈拉濱; T細胞急性白血病; 周圍神經病變; Nelarabine; T-cell acute lymphoblastic leukemia; Peripheral neuropathy; |
語 文 | 英文(English) |
中文摘要 | 最近幾十年來,對於 T 細胞急性淋巴性白血病的治療已經有許多進步,大大改善了 這類病人的完全緩解率。然而,其中仍有部分病人在兩年內疾病就重新復發,且對之後 的化學治療反應不佳。Nelarabine,為新一代的嘌呤類似物,FDA 已經批准其用於至少 2 種化療方案治療無效或治療後復發的 T 細胞急性淋巴細胞性白血病,但是同時也有案例 報告 nelarabine 導致的神經學毒性。我們報告的病例是一位 37 歲的男性,在 T 細胞急性 淋巴性白血病復發時,接受了三個周期的 nelarabine,之後產生雙下肢無力,感覺異常及 失禁的症狀。這些症狀逐漸加劇,病人在一周內變得無法行走站立至完全癱瘓,而且神 經學症狀在停藥後並無改善。這位病人在兩個月後因為疾病惡化而過世。我們應了解 nelarabine 可能產生的毒性,並在使用 nelarabine 治療時,提高警覺,小心監測病人的神 經學症狀。 |
英文摘要 | Although current treatment can improve the complete remission rate of T-cell acute lymphoblastic leukemia (T-ALL), approximately half of the patients relapse within the first 2 years and have poor prognosis. Nelarabine is a novel purine nucleoside analog, and has been proven efficacious against both refractory and relapsed T-ALL. However, its adverse neurological effects are also well recognized. We report a 37-year-old patient with relapsed T-ALL who developed weakness and paresthesia over the lower limbs bilaterally, with difficulty urinating, after three cycles of nelarabine were administered as bridging therapy to allogeneic stem cell transplantation. The patient’s symptoms were irreversible and progressed to complete paraplegia in a week, and he expired due to disease progression after two months. Notwithstanding the proven efficacy of nelarabine, the drug’s potentially lethal neurological toxicity should always be carefully monitored during therapy. |
本系統中英文摘要資訊取自各篇刊載內容。